(VIANEWS) – Kite Realty Group Trust (KRG), Ares Capital (ARCC), CME Group (CME) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up to now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. Kite Realty Group Trust (KRG)
2275% Payout Ratio
Kite Realty Group Trust is a full-service, vertically integrated real estate investment trust (REIT) that provides communities with convenient and beneficial shopping experiences. We connect consumers to retailers in desirable markets through our portfolio of neighborhood, community, and lifestyle centers. Using operational, development, and redevelopment expertise, we continuously optimize our portfolio to maximize value and return to our shareholders.
Earnings Per Share
As for profitability, Kite Realty Group Trust has a trailing twelve months EPS of $0.04.
PE Ratio
Kite Realty Group Trust has a trailing twelve months price to earnings ratio of 509.5. Meaning, the purchaser of the share is investing $509.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.26%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jul 5, 2023, the estimated forward annual dividend rate is 0.96 and the estimated forward annual dividend yield is 4.72%.
2. Ares Capital (ARCC)
147.06% Payout Ratio
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.
Earnings Per Share
As for profitability, Ares Capital has a trailing twelve months EPS of $1.27.
PE Ratio
Ares Capital has a trailing twelve months price to earnings ratio of 13.9. Meaning, the purchaser of the share is investing $13.9 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.51%.
Sales Growth
Ares Capital’s sales growth is 42.1% for the ongoing quarter and 32.4% for the next.
3. CME Group (CME)
109.14% Payout Ratio
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, CME Group has a trailing twelve months EPS of $7.89.
PE Ratio
CME Group has a trailing twelve months price to earnings ratio of 23.3. Meaning, the purchaser of the share is investing $23.3 for every dollar of annual earnings.
Earnings Before Interest, Taxes, Depreciation, and Amortization
CME Group’s EBITDA is 13.13.
Moving Average
CME Group’s worth is below its 50-day moving average of $186.81 and under its 200-day moving average of $183.89.
Volume
Today’s last reported volume for CME Group is 1108710 which is 35.13% below its average volume of 1709260.
Previous days news about CME Group (CME)
- According to FXStreet on Wednesday, 3 May, "In light of advanced prints from CME Group for natural gas futures markets, open interest rose for the fifth day in a row on Tuesday, this time by around 28.5K contracts, the largest single day advance so far this year. "
- According to FXStreet on Wednesday, 3 May, "According to the CME Group FedWatch Tool, the probability of the US central bank raising its policy rate one more time in June is virtually 0%, compared to nearly 40% just a week ago."
4. Fresenius Medical Care AG (FMS)
57.19% Payout Ratio
Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Earnings Per Share
As for profitability, Fresenius Medical Care AG has a trailing twelve months EPS of $1.27.
PE Ratio
Fresenius Medical Care AG has a trailing twelve months price to earnings ratio of 18.22. Meaning, the purchaser of the share is investing $18.22 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.08%.
Sales Growth
Fresenius Medical Care AG’s sales growth is 14.3% for the current quarter and 11.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 62.9% and a negative 24.3%, respectively.
Yearly Top and Bottom Value
Fresenius Medical Care AG’s stock is valued at $23.14 at 20:23 EST, way under its 52-week high of $34.62 and way higher than its 52-week low of $12.79.
5. Eli Lilly and Company (LLY)
56.81% Payout Ratio
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.73.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 63.49. Meaning, the purchaser of the share is investing $63.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.67%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Feb 13, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 1.2%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 51.2% and 12.1%, respectively.
